Joel C. Marrs, PharmD, MPH, FAHA, FASHP, FCCP, FNLA, BCACP, BCCP, BCPS, CLS

Joseph Saseen, PharmD; and Joel C. Marrs, PharmD, discuss key updates in the 2026 dyslipidemia guidelines and their implications for clinical and pharmacy practice.

2026 dyslipidemia guideline updates highlight earlier risk-based lipid management, expanded biomarker use, and a growing pharmacist role in cardiovascular prevention.

Pharmacists play a central role in shared decision-making by guiding patients through lipid-lowering options, cost considerations, and ongoing monitoring aligned with updated dyslipidemia guidelines.

Pharmacists can improve statin adherence and refine triglyceride management by leveraging patient-centered counseling, adherence strategies, and updated guideline recommendations prioritizing statins and targeted adjunctive therapies.

Pharmacists play a central role in implementing new dyslipidemia guidelines, including ApoB testing, earlier risk assessment, and expanded use of combination lipid-lowering therapy.

This Continuing Education activity is supported by an educational grant from Amgen.